<DOC>
	<DOC>NCT00967746</DOC>
	<brief_summary>This is a phase 2, randomized, active-controlled, parallel-group, multicenter, single-blind trial of three different doses of etonogestrel releasing medicated intrauterine systems (ENG-MIUS) in healthy parous women in need for contraception. The primary trial objective is to explore safety and acceptability of three doses of an ENG-releasing medicated intrauterine system (ENG-MIUS) as compared to Multiload-cu 375Â®.</brief_summary>
	<brief_title>An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)</brief_title>
	<detailed_description />
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Healthy female subjects in need for contraception will be selected to participate in the trial; Each subject must be &gt;=18 to &lt;=40 years of age at screening and in need for contraception; Each subject must have given birth to at least one child (gestational age &gt;=28 weeks); Each subject must have a uterus with a measured length between 6.0 and 9.0 cm (extremes included) from external os to fundus uteri. A subject must not be pregnant or suspected to be pregnant; A subject must not have had an ectopic pregnancy in the past or must not have a history or presence of predisposing factors for this condition such as salpingitis, endometritis or pelvic peritonitis; A subject must not have a history or presence of any malignancy; A subject must not have a history or presence of premalignant disease of the uterus or cervix, including endometrial hyperplasia, or (other) sexsteroid sensitive premalignancies; A subject must not have an active venous thromboembolic disorder (e.g. deep vein thrombosis, pulmonary embolism); A subject must not have a history or presence of severe hepatic disease with AST and/or ALT levels of &gt;=3 times the upper normal limit; A subject must not have congenital or acquired malformations or distortions of the uterus or cervix; A subject must not have large or multiple uterine fibromyomata, or a smaller uterine fibromyoma which may interfere with the insertion of the MIUS/IUD according to the investigator; A subject must not have vaginal bleeding of undiagnosed etiology; A subject must not have dysmenorrhea interfering with daily activities or menorrhagia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>